Edition:
United Kingdom

AbbVie Inc (ABBV.N)

ABBV.N on New York Stock Exchange

89.50USD
18 Jan 2019
Change (% chg)

$2.30 (+2.64%)
Prev Close
$87.20
Open
$87.90
Day's High
$89.53
Day's Low
$86.95
Volume
2,068,556
Avg. Vol
1,812,599
52-wk High
$125.84
52-wk Low
$77.50

Latest Key Developments (Source: Significant Developments)

Abbvie Says Non-Humira Sales To Grow To More Than $35 Bln In 2025
Wednesday, 9 Jan 2019 

Jan 9 (Reuters) - AbbVie Inc ::ABBVIE INC SAYS NON-HUMIRA SALES TO GROW TO MORE THAN $35 BILLION IN 2025- JP MORGAN CONF.ABBVIE INC SAYS MAVYRET WILL REMAIN A STRONG SOURCE OF CASH FLOW OVER LONG RANGE PLAN PERIOD - JP MORGAN CONF.ABBVIE INC EXPECTS ELAGOLIX FOR ENDOMETRIOSIS AND UTERINE FIBROIDS TO BRING IN OVER $2 BILLION IN SALES BY 2025 - JP MORGAN CONF.ABBVIE INC EXPECTS HEMATOLOGIC ONCOLOGY FRANCHISE TO BRING IN OVER $9 BILLION IN SALES BY 2025 - JP MORGAN CONF.ABBVIE INC EXPECTS IMMUNOLOGY DRUGS UPADACITINIB AND RISANKIZUMAB TO BRING IN OVER $10 BILLION IN SALES BY 2025 - JP MORGAN CONF.ABBVIE PRESIDENT MICHAEL SEVERINO SAYS CO EXPECTS TO DRIVE STRONG GROWTH IN 2019 EVEN AS IT FACES DIRECT BIOSIMILAR COMPETITION ACROSS MAJORITY OF INTERNATIONAL MARKETS - JP MORGAN CONF.ABBVIE INC EXPECTS HUMIRA TO REMAIN MARKET LEADER THROUGH 2022 - JP MORGAN CONF.ABBVIE INC EXPECTS ONCOLOGY TO BE MAJOR GROWTH DRIVER OVER NEXT DECADE AND BEYOND- JP MORGAN CONF.ABBVIE INC EXPECTS HCV WILL BE A DURABLE MARKET INTO THE 2020'S - JP MORGAN CONF.ABBVIE PRESIDENT MICHAEL SEVERINO SAYS "WE WILL CONTINUE TO AUGMENT OUR PIPELINE THROUGH STRATEGIC LICENSING, ACQUISITIONS AND PARTNERING" - JP MORGAN CONF.ABBVIE PRESIDENT MICHAEL SEVERINO SAYS CO IS "ALWAYS LOOKING" TO GROW BUSINESS, IS COMMITTED TO GROWING DIVIDEND AND WILL BUY BACK SHARES OPPORTUNISTICALLY - JP MORGAN CONF.  Full Article

Abbvie Announces Executive Leadership Changes
Monday, 17 Dec 2018 

Dec 17 (Reuters) - AbbVie Inc ::ABBVIE ANNOUNCES EXECUTIVE LEADERSHIP CHANGES.ABBVIE INC - MICHAEL E. SEVERINO CO'S EVP , RESEARCH & DEVELOPMENT & CHIEF SCIENTIFIC OFFICER, HAS BEEN NAMED VICE CHAIRMAN AND PRESIDENT.ABBVIE INC - LAURA J. SCHUMACHER HAS BEEN NAMED VICE CHAIRMAN, EXTERNAL AFFAIRS AND CHIEF LEGAL OFFICER.ABBVIE INC - CARLOS ALBAN, WHO CURRENTLY SERVES AS EVP, COMMERCIAL OPERATIONS, HAS BEEN NAMED VICE CHAIRMAN, CHIEF COMMERCIAL OFFICER.  Full Article

Abbvie Announces $5 Bln Increase To Stock Repurchase Program
Thursday, 13 Dec 2018 

Dec 13 (Reuters) - AbbVie Inc ::ABBVIE ANNOUNCES $5 BILLION INCREASE TO STOCK REPURCHASE PROGRAM.  Full Article

AbbVie Inc - Phase 3 Trial Of Rova-T As Second-Line Therapy For Advanced Small-Cell Lung Cancer Halted
Wednesday, 5 Dec 2018 

Dec 5 (Reuters) - AbbVie Inc ::PHASE 3 TRIAL OF ROVA-T AS SECOND-LINE THERAPY FOR ADVANCED SMALL-CELL LUNG CANCER (TAHOE STUDY) HALTED.INDEPENDENT DATA MONITORING COMMITTEE RESPONSIBLE FOR ONGOING REVIEW OF STUDY DATA RECOMMENDED ENROLLMENT BE STOPPED.INDEPENDENT DATA MONITORING COMMITTEE RESPONSIBLE FOR ONGOING REVIEW OF STUDY DATA RECOMMENDED ENROLLMENT BE STOPPED.RECOMMENDATION FROM IDMC TO HALT ENROLLMENT APPLIES ONLY TO TAHOE STUDY AND DOES NOT IMPACT OTHER ROVA-T CLINICAL STUDIES.AN IDMC RECOMMENDED STOPPING ENROLLMENT IN TAHOE DUE TO SHORTER OVERALL SURVIVAL IN ROVA-T ARM COMPARED WITH TOPOTECAN CONTROL ARM.  Full Article

Genentech Says FDA Approves Venclexta in Newly-Diagnosed AML
Wednesday, 21 Nov 2018 

Nov 21 (Reuters) - Genentech::GENENTECH - FDA GRANTED ACCELERATED APPROVAL TO VENCLEXTA, IN COMBINATION WITH A HYPOMETHYLATING AGENT, OR LOW-DOSE CYTARABINE IN NEWLY-DIAGNOSED AML.  Full Article

Medicines Patent Pool Signs Licence With AbbVie To Expand Access To Hep-C Treatment glecaprevir/pibrentasvir
Monday, 12 Nov 2018 

Nov 12 (Reuters) - The Medicines Patent Pool:THE MEDICINES PATENT POOL SIGNS LICENCE WITH ABBVIE TO EXPAND ACCESS TO KEY HEPATITIS C TREATMENT, GLECAPREVIR/PIBRENTASVIR.MEDICINES PATENT POOL SAYS COLLABORATION WITH ABBVIE WILL ENSURE AFFORDABLE HEPATITIS C TREATMENT OPTIONS IN LOW- AND MIDDLE-INCOME COUNTRIES .  Full Article

Abbvie Receives European Commission Approval Of Venclyxto Plus Rituximab For Treatment Of Patients With Chronic Lymphocytic Leukemia Who Have Received At Least One Prior Therapy
Thursday, 1 Nov 2018 

Nov 1 (Reuters) - AbbVie Inc ::ABBVIE RECEIVES EUROPEAN COMMISSION APPROVAL OF VENCLYXTO® (VENETOCLAX) PLUS RITUXIMAB FOR THE TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY.APPROVAL IS BASED ON MURANO PHASE 3 CLINICAL TRIAL.  Full Article

Galapagos 9-Month Revenue Rises To 205.1 Million Euros
Wednesday, 24 Oct 2018 

Oct 25 (Reuters) - GALAPAGOS ::REPORTED ON WEDNESDAY 9-MONTH GROUP REVENUES INCREASED BY EUR 98.7 MILLION TO EUR 205.1 MILLION.9-MONTH OPERATING LOSS DECREASED BY EUR 9.1 MILLION TO EUR 53.5 MILLION.9-MONTH NET LOSS DECREASED BY EUR 41.7 MILLION TO EUR 44.2 MILLION.CASH AND CASH EQUIVALENTS ON 30 SEPT 2018 OF EUR1,343.7 MILLION.IN Q4, EXPECTS TO PRESENT MORE DETAILED FINDINGS FROM THE EQUATOR, TORTUGA, AND FINCH 2 TRIALS WITH FILGOTINIB.WILL ALSO PRESENT FIRST DATA AND DEVELOPMENT STRATEGY WITH REGARD TO TOLEDO, OUR NEW PROGRAM IN INFLAMMATORY INDICATIONS.EXPECT TO START DOSING IN THE ISABELA (PH3 IPF `1690) AND PINTA (PH2 IPF `1205) PATIENT TRIALS.DUE TO REVISION OF THE ABBVIE COLLABORATION AGREEMENT IN CF, CO IS REDUCING EXPECTED OPERATIONAL CASH BURN FROM THE LAST GUIDED EUR180-200 MILLION TO EUR140-160 MILLION IN 2018.  Full Article

Positive Phase 2B Data For AbbVie's Upadacitinib Show Significant Induction Of Clinical Remission, Response In Patients
Monday, 22 Oct 2018 

Oct 22 (Reuters) - AbbVie Inc ::POSITIVE PHASE 2B DATA FOR ABBVIE'S UPADACITINIB SHOW SIGNIFICANT INDUCTION OF CLINICAL REMISSION AND RESPONSE IN PATIENTS WITH ULCERATIVE COLITIS.IN U-ACHIEVE, UPADACITINIB (15/30/45 MG, ONCE DAILY) MET PRIMARY ENDPOINT OF CLINICAL REMISSION & ALL RANKED SECONDARY ENDPOINTS.UPADACITINIB 7.5 MG GROUP DID NOT MEET PRIMARY ENDPOINT.SERIOUS ADVERSE EVENTS OCCURRED IN 0/4/6/5 PERCENT OF 7.5/15/30/45 MG UPADACITINIB GROUPS, RESPECTIVELY.NO NEW SAFETY SIGNALS WERE DETECTED IN STUDY.NO VENOUS THROMBOEMBOLIC EVENTS, MAJOR ADVERSE CARDIOVASCULAR EVENTS OR DEATHS OCCURRED.OVERALL SAFETY PROFILE WAS CONSISTENT WITH THAT OBSERVED IN PREVIOUSLY REPORTED PHASE 2 CROHN'S DISEASE STUDY.PHASE 3 TRIALS FOR UPADACITINIB IN ULCERATIVE COLITIS HAVE BEEN INITIATED.  Full Article

AbbVie Says Robert Michael Appointed CFO
Friday, 19 Oct 2018 

Oct 19 (Reuters) - AbbVie Inc ::SAYS ROBERT A. MICHAEL APPOINTED CFO.WILLIAM J. CHASE, EXECUTIVE VICE PRESIDENT, CHIEF FINANCIAL OFFICER, INFORMED ABBVIE THAT HE PLANS TO RETIRE FROM COMPANY IN MID-2019.ABBVIE SAYS WILLIAM J. CHASE, EXECUTIVE VICE PRESIDENT, CHIEF FINANCIAL OFFICER, INFORMED ABBVIE THAT HE PLANS TO RETIRE FROM THE COMPANY IN MID-2019.  Full Article

UPDATE 1-AbbVie's Imbruvica fails to meet main goal in pancreatic cancer study

Jan 18 AbbVie Inc said on Friday its blockbuster cancer treatment in combination with chemotherapy agents failed to meet the main goal in a late-stage study of patients with a form of pancreatic cancer.